Collectively, this study provided preclinical support for using capmatinib for the treatment of osimertinib-resistant NSCLC cells, by ways of inhibiting MET/Akt/Snail signaling and CAF transformation (Figure 6). The gene discussed is AKT1; the disease is non-small cell lung carcinoma.